Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.85 |
| ▸ | RAB9A | P51151 | 4/20 | 0.85 |
| ▸ | JAK2 | O60674 | 2/20 | 0.85 |
| ▸ | JAK1 | P23458 | 1/20 | 0.85 |
| ▸ | MAOB | P27338 | 2/20 | 0.74 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.65 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.65 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.65 |
| ▸ | CLK2 | P49760 | 1/20 | 0.65 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.65 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.65 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15764657 | 0.92 | JAK2 (1.00) | NPC1RAB9AJAK2JAK1MAOB | |
| SCHEMBL15764674 | 0.84 | ROCK2 (0.75) | NPC1RAB9AJAK2MAOBDYRK3 | |
| SCHEMBL3380296 | 0.82 | NPC1 (1.00) | NPC1RAB9AJAK2JAK1DYRK3 | |
| SCHEMBL18668994 | 0.81 | MAOB (0.84) | NPC1RAB9AJAK2JAK1MAOB | |
| SCHEMBL5415117 | 0.80 | MAOB (0.80) | NPC1RAB9AJAK2MAOBDYRK3 | |
| SCHEMBL15764676 | 0.79 | NPC1 (1.00) | NPC1RAB9AJAK2MAOBDYRK3 | |
| SCHEMBL15764669 | 0.79 | NPC1 (0.76) | NPC1RAB9AJAK2JAK1MAOB | |
| SCHEMBL15764661 | 0.79 | NPC1 (0.74) | NPC1RAB9AJAK2MAOBDYRK3 | |
| SCHEMBL25131975 | 0.79 | NPC1 (0.75) | NPC1RAB9AJAK2JAK1MAOB | |
| SCHEMBL5401343 | 0.78 | NPC1 (0.65) | NPC1RAB9AJAK2JAK1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | claimed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
| WO-2009103778-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | IL1B, LITAF, CYP11B1 | NPC1 145/4885RAB9A 2083/4885JAK2 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.